Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055718 · ClinicalTrials.gov registry record · Phase 2
Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy
A Phase 2 study, sponsored by Herbert Irving Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00055718 is a Phase 2 study that has completed, run by Herbert Irving Comprehensive Cancer Center. The registered enrollment target is 50 participants.
The verdict
NCT00055718, a Phase 2 study, has completed, sponsored by Herbert Irving Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
RATIONALE: Silymarin (milk thistle extract) is an herb that may be effective in treating liver disorders caused by cancer therapy. PURPOSE: Randomized phase II trial to study the effectiveness of silymarin in treating patients who have acute lymphoblastic leukemia with chemotherapy-related side effects to the liver.
Interventions
- DIETARY_SUPPLEMENT silymarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2001-11 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055718
The ClinicalTrials.gov registry entry for NCT00055718 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Herbert Irving Comprehensive Cancer Center, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which silymarin is the first listed.
NCT00055718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00055718 about?
NCT00055718 is a clinical study titled "Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy". RATIONALE: Silymarin (milk thistle extract) is an herb that may be effective in treating liver disorders caused by cancer therapy. PURPOSE: Randomized phase II trial to study the effectiveness of silymarin in treating patients who have acute lymphoblastic leukemia with chemotherapy-related side eff...
What is the current status of trial NCT00055718?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2001-11. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00055718?
The interventions under investigation include: silymarin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00055718?
This trial is sponsored by Herbert Irving Comprehensive Cancer Center, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.